F10 and acute coronary syndrome: In particular, the combination of aspirin with a low-dose of the selective direct factor Xa inhibitor rivaroxaban at the dosage of 2.5 mg b.i.d. was shown to reduce the rates of CV death and all-cause death (2.9% vs. 4.5%; HR, 0.68; 95% CI, 0.53–0.87) compared with placebo in the ATLAS ACS 2-TIMI 51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome 2–Thrombolysis in Myocardial Infarction 51), enrolling 15 526 patients with acute coronary syndromes [44].